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Abstract
Background: Previous epidemiological studies have inconsistently shown a modestly increased
breast cancer risk associated with hormone replacement therapy (HRT). Limited information is
available about different formulations – particularly concerning different progestins.
Methods: A case-control study was performed within Germany in collaboration with regional
cancer registries and tumor centers. Up to 5 controls were matched breast cancer cases.
Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios
(OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to compare the
risk of different estrogens, progestins, and combinations.
Results: A total of 3593 cases of breast cancer were identified and compared with 9098 controls.
The adjusted overall risk estimate for breast cancer (BC) associated with current or past use of
HRT was 1.2 (1.1–1.3), and almost identical for lag times from 6 months to 6 years prior to
diagnosis. No significant trend of increasing BC risk was found with increasing duration of HRT use,
or time since first or last use in aggregate. Many established BC risk factors significantly modified
the effect of HRT on BC risk, particularly first-degree family history of BC, higher age, lower
education, higher body mass index (BMI), and never having used oral contraceptives (OCs) during
lifetime.
Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT
formulation groups (estrogens, progestins, and combinations) were too small for strong
conclusions. Nevertheless, the BC risk seems not to vary much across HRT formulation subgroups.
In particular, no substantial difference in BC risk was observed between HRT containing conjugated
equine estrogens (CEE) or medroxyprogesterone acetate (MPA) and other formulations more
common in Europe.
Conclusion: The BC risk of HRT use is rather small. Low risk estimates for BC and a high
potential for residual confounding and bias in this observational study do not permit causal
conclusions. Apparently, there is not much variation of the BC risk across HRT formulations
(estrogens, progestins). However, the small numbers and the overlapping nature of some of the
subgroups suggest cautious interpretation.
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Background
Discussion surrounding the role of steroid hormone for-
mulations in carcinogenesis is complex, i.e. providing
arguments for both benefits and risks in short and long-
term use [1] In 1968 discussion of benefits and adverse
effects was launched in large part following publication of
the study by the Royal College of General Practitioners
[2]. Specific discussion of adverse effects of estrogens or
estrogen/progestin combinations used for the alleviation
of vasomotor symptoms of peri- and post-menopausal
women – called Hormone Replacement Therapy (HRT) –
hit its peak with the publication of the Women's Health
Initiative (WHI) Study [3] and the Million Women Study
(MWS) [4].
In addition to their efficacy for the treatment of vasomo-
tor symptoms benefits of HRT have been shown by obser-
vational studies and clinical trials for the prevention of
osteoporosis and fractures [5,6], as well as lower risk of
endometrial and colorectal cancer [4,5,7]. Furthermore,
many observational studies of HRT have been associated
with a 40–50% lower risk of acute cardiovascular events in
women using hormone replacement therapy (less often
for combinations with progestins) [8,9]. However, this
was not confirmed by the WHI study. It is not clear
whether HRT has an impact on real primary prevention of
cardiovascular diseases [10,11].
The overall risk of breast cancer associated with HRT has
shown variation, but has mainly been reported as signifi-
cantly increased but well under a risk estimate of 2.0
[12,13]. In previous publications, we have shown no
increased risk for gynecologic cancers at least – and in fact
even weak evidence for preventive properties of sex ster-
oids in young women using oral contraceptives [14-16].
The WHI study results [3] published in 2002 for breast
cancer (BC) and HRT use that showed a significantly
increased association with estrogen plus progestin treat-
ment based on combined hormonal therapy of conju-
gated equine estrogens (CEE) with medroxyprogesterone
acetate (MPA). This combination is the most commonly
used HRT in North America. In Europe, however, the most
common HRT preparations are based on estradiol.
The objective of this publication is to present data on BC
risk associated with HRT use in Germany were CEE/MPA
is less frequently used than formulations based on estra-
diol and a large series of progestin other than MPA. This
paper is also focused on the question of different BC risk
in different HRT formulation sub-groups.
Methods
Objectives
The objective of this case-control study was to provide evi-
dence regarding the presence or absence of differential
effects of HRT formulations used in Europe on cancer
risks or benefits in collaboration with German cancer reg-
istries and tumor centers. The study was planned in early
2003 (performed 2004–2005), and was justified by the
working hypothesis that the results obtained with the
HRT formulation CEE/MPA might be not generalizable
for Europe with HRTs of other estrogens and progestins.
This study on HRT was made possible by earlier collabo-
rative research with German cancer registries and tumor
centers in the field of gynecological cancer and exogenous
steroid hormone use [14-16]. The study was designed as a
case-control study with lifetime history of exposure and
information about patient's characteristics as well as risk
factors for BC.
Cancer registries in Schleswig Holstein, Hamburg, and the
common registry for the "five new states" (former East
Germany) participated in this study, as well as clinical
tumor centers throughout Germany.
The exposure data (sex steroid hormone use) were
recorded by month and year of exposure (type, brand
name) as well as the date of diagnosis of cancer. The infor-
mation was compiled primarily based on a questionnaire.
The cancer registries distributed the questionnaires to the
breast cancer cases. The participation was voluntary and a
consent form was required.
The study protocol and questionnaire were approved by
the relevant Ethical Committee and the Office of Data Pri-
vacy.
The Centre for Epidemiology & Health Research Berlin
(ZEG Berlin) coordinated the study. A number of univer-
sity-based and other collaborators contributed with ideas/
proposals to the study, specific sub-studies, evaluation,
and interpretation.
Cases and controls
Eligible cases were those of histologically confirmed
breast cancer (ICD 10: C50) diagnosed until 2004 inclu-
sively in women of all age groups. The vast majority got
their breast cancer diagnosed between 2000 and 2004, but
7% before 2000. Subjects had to be alive and in suffi-
ciently good shape to complete the questionnaire in order
to qualify as cases for the study. Cases were considered
non-eligible if they showed a history of other malignant
tumors or missing time variables (diagnosis, exposure).
An initial total of 3717 BC cases were identified. Of these,
124 cases were excluded for different reasons: in 66 cases
the diagnosis was not fully confirmed, and 58 had a uter-
ine or ovarian cancer before or in the same time window
as BC. Thus 3593 BC cases were used for this analysis.BMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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The participants of the German Cohort Study on
Women's Health, that were shown to be representative for
German Women in many aspects [14-17], were used as
pool for controls (if without history of malign tumors).
Up to five controls were matched for each BC case for
same age as case (year of birth +/- two years) and residency
(Bundesland) as matching criteria. Of a total of 18,898
potential controls, we found 9098 matched controls for
3593 breast cancer cases.
Data collection, variables and database preparation
Time-related information on lifetime history of hormone
use as well as data on reproductive life, lifestyle pattern,
conditions/diseases, and some other factors were
obtained via a self-administered postal baseline question-
naire. Other studies have shown that the recall of hor-
mone use history (type and duration of use) can be
reliably obtained from women even for periods far in the
past [18-20]. The same data were obtained from cases and
controls. Many consistency checks were made. Telephone
inquiries with respondents were conducted to improve
the data quality, if questionnaire data were inconsistent,
not sufficiently clear, or missing.
The type of HRT formulation was classified into five broad
categories: estrogen/progestin alone, combination type,
estrogen type, progestin type, and CEE/MPA category. The
lifetime history of HRT use was divided into multiple sub-
groups: "only HRTs" (estrogen only and progestagen
only), combination form (sequential, continuous-com-
bined, and all E+P together), according to the estrogen
type (estradiol, E2, EE, CEE), according to progestins
(NETA, norgestrel, LNG, MPA, CMA, CPA, medrogestone,
dydrogesterone, hydroxyprogesterone desogestrel,
lynestrenol, progesterone, dienogest, tibolone,
raloxifene), and mutually exclusive categories of CEE/
MPA combinations (CEE+MPA, CEE or MPA, no CEE &
no MPA). Each participant who had ever used HRT was
classified in accordance with these categories, which are
not mutually exclusive but rather overlapping, i.e. women
might have used more than one of the HRT formulations
during lifetime and therefore counted more than once. In
many of these subgroups, we expected to run out of num-
bers because of low exposure prevalence.
Index dates
We considered an important possible bias for analysis
using the logistic regression model: The possibility cannot
be excluded that prior to the final diagnosis of breast can-
cer, the women and/or their physicians might have been
aware of "warning signs" (e.g. breast lumps, suspicious
areas in mammograms) that may have led to a decision
not to use HRT. In addition, knowledge about HRT might
have led to more intense screening/diagnostics for early
forms of cancer. We therefore introduced several index
dates (= different lag times): For example, we disregarded
HRT use and other exposure information in the last six
months prior to the final cancer diagnosis across all anal-
yses, i.e. for both cases and controls. A series of further
index dates was introduced, such as 2, 4, and 6 years, i.e.
all exposure-related information prior to these dates was
ignored in the respective analyses. It may be debated
whether 6 years prior to diagnosis is too long a period to
disregard information, because HRT use during the 6
years before diagnosis might well have promoted tumor
growth leading to earlier diagnosis. Attempts to establish
whether this is a problem were undertaken by analyzing
the effect of increasing length of time since first and last
HRT use as well as duration of use.
The analytic model
The main analysis was done with conditional logistic
regression. Crude and adjusted odds ratios (OR) were
reported with 95% confidence intervals (95% CI). Adjust-
ment was done for BMI, family history of breast/uterine/
ovarian cancer, child-bearing history, age at first live birth,
duration of breast-feeding, age at menarche, OC use, and
education. If values were missing for the adjustment vari-
ables, we used automatically imputed figures such as
modal values. For sub-group analyses where the matching
effect got lost due to other group definitions (HRT formu-
lation subgroups), we adjusted for age and residency to
replace the matching. We were not able to use age at men-
opause as co-variable because it could not be reliably
determined for a high proportion of participants.
The number of cancer cases was – despite the large total
number – too small for many sub-analyses (e.g. HRT for-
mulation subgroups), we refrained from complex adjust-
ment to prevent unstable risk estimates, and i.e. we
adjusted only for age and residency. Moreover, we did not
calculate risk estimates if any cell of the "two-by-two"
table contained less than 5 women.
We analyzed the impact of duration of HRT use compared
to never-use (categories: never, <2 years, 2–4 years, 5–7
years, and 8+ years). The time elapsed from first HRT use
to the manifestation of BC was categorized as follows:
never-use, 1–4 years, 5–9 years, 10–14 years, 15+ years.
The respective categories for time since last use were:
never-use, <1 year, 1–2 years, 3–4 years, and 5+ years ago.
Short use (less than 1 year) might be differently recalled
by women with cancer cases versus those without cancer
(if longer ago).
It was not possible to define mutually exclusive exposure
categories to analyze individual HRT formulations. Use of
HRT formulations partly overlaps across life histories due
to switching pattern. Furthermore, it was not feasible to
define sufficiently large groups with exclusive use of onlyBMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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one specific hormonal formulation group. Therefore,
comparison of risk estimates across exposure groups pro-
vides only an impression as to whether there are substan-
tial differences in cancer risk.
We abstained also from defining categories of HRTs or
compounds "longest used during lifetime", because of the
arbitrary character of the decision as well as the assumed
incompatibility for what "longest" might mean across dif-
ferent compounds.
The statistical packages SAS 9.1 and STATA 8.0 were used.
Results
Case/non-case characteristics
Table 1 describes the breast cancer cases and the matched
controls. The mean age of the cancer cases and matched
controls was similar as was age at menarche and age at
first live birth. The educational level was slightly higher in
the control group than case group.
Other descriptive data in Table 1 refer to known risk fac-
tors for breast cancers that were used as adjustment factors
in the analyses. Controls had more children, more often
breast-feeding, had more frequently a history of OC use,
but less frequently ever used HRT than cases. The BMI was
somewhat lower in controls and family history of breast
cancer was less prevalent than in cases. Most of these var-
iables were used to control for confounding in the main
analyses of BC risk.
Ever-never HRT use by index date
We analyzed the cancer risk of HRT ever use vs. never use
(Table 2) with conditional logistic regression with differ-
ent lag-time (index dates) between HRT-exposure and
cancer diagnosis. A marginally increased risk (OR 1.2) was
observed for breast cancer with little variation across all
index dates, i.e. allowing a lag-time from 6 months to 6
years between HRT exposure and breast cancer diagnosis.
Little difference was also found between crude and
adjusted relative risk estimates. The adjusted risk esti-
mates obtained in the matched and unmatched did not
differ (data not shown).
Table 1: Characteristics of breast cancer cases and controls.
Breast cancer N = 3593 BC controls N = 9098
Age at diagnosis (mean, SD) 54.6 9.3 50.6 10.1
N% N %
Education
University level 1066 29.7 3215 35.3
Lower education 2483 69.1 5817 63.9
Age at menarche
< 13 years 1926 53.6 4870 53.5
13 + years 1583 44.1 3998 43.9
Child bearing history
0–1 child 1524 42.4 3358 36.9
2+ children 1992 55.4 5648 62.1
Age at first live birth
<= 22 years 1502 41.8 3821 42.0
> 22 years 1626 45.3 4276 47.0
Nulliparous & no live birth 367 10.2 840 9.2
Breast-feeding
never 1924 53.6 3957 43.5
1 month and more 1592 44.3 5047 55.5
OC use
never 1079 30.0 1805 19.8
ever 2508 69.8 7271 79.9
HRT use
never 2080 57.9 5910 65,0
ever 1513 42.1 3188 35.0
Family history of breast cancer
No 2453 68.3 8400 92.3
Yes 550 15.3 649 7.1
Body mass index
<25 1415 39.4 4470 49.1
25 + 2152 59.9 4508 49.6BMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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Time-related exposure
Table 3 demonstrates the effect of duration of HRT use, of
the time since first HRT use and time elapsed since last
HRT use on risk of breast cancers; this table depicts only
results at index date 0.5 year.
Duration of HRT use was apparently very little associated
with breast cancer risk in our study. Two slightly increased
risk estimates were observed (OR about 1.2, only margin-
ally significant): duration up to 2 years and 8+ years. No
significant trend of increasing breast cancer risk with
increasing duration of HRT use was found.
Up to 10 years since first use the risk marginally increased
in the two lower categories (up to 10 years until diagno-
sis). The risk estimates varied between 1.0 and 1.2 – and
without trend of increasing risk with increasing time of
diagnosis since first use.
Similarly, no trend of increasing cancer risk with increas-
ing time since last HRT use was seen. The risk estimates
were not significant and close to 1.0, with the exception of
a non-significant cancer risk estimate for 5 years and more
since last HRT use (small numbers).
Effect modification
Established risk markers for breast cancer such as age at
diagnosis (or at menarche, or first live birth), number of
live births, breast feeding, OC use, BMI, family history of
BC, or education were analyzed for modifying the associ-
ation of HRT use and BC. All variables in Table 4 signifi-
cantly modified the association between HRT use and BC
in this study, although the risk differences between each
of the two strata were apparently small. Only the BC risk
of women with first-degree family history of BC and use
of HRT was remarkably higher than in women without
family history. Much less obvious effect modifications
Table 2: Risk of breast cancer associated with HRT: Ever- use of HRT use vs. never use analyzed with conditional logistic regression by 
increasing lag-time (index dates).
Breast cancer Conditional logistic regressions by index dates: OR (95% CI)
No index date 0.5 2.0 4.0 6.0
Crude 1.1 (0.99–1.2) 1.1 (0.99–1.2) 1.1 (0.99–1.2) 1.2 (1.0–1.3) 1.2 (1.0–1.3)
Adjusted 1.2 (1.1–1.3) 1.2 (1.0–1.3) 1.2 (1.0–1.3) 1.2 (1.1–1.4) 1.2 (1.1–1.4)
Conditional logistic regression analysis [Odds ratios (OR) and 95% confidence intervals]; adjustment for BMI, family history of breast cancer, 
childbearing history, age at first live birth, duration of breast-feeding, age at menarche, ever OC use, education. Index dates 0.5 to 6.0 = exposure 
information was not considered 0.5, 2.0, 4.0, and 6.0 years prior to cancer diagnosis.
Table 3: Risk of breast cancer associated with HRT: Ever- use vs. never use of HRT.
e-case1 e-ctrl.1 Crude OR (95% CI) Adj. OR (95% CI)
Ever HRT 1492 3142 1.1 (0.99–1.2) 1.2 (1.0–1.3)
Duration of use2
<2 yrs 387 770 1.3 (1.1–1.5) 1.3 (1.1–1.6)
2–4 yrs 223 670 0.8 (0.7–0.9) 0.9 (0.7–1.1)
5–7 yrs 278 609 1.0 (0.9–1.2) 1.1 (0.9–1.3)
8+ yrs 604 1093 1.2 (1.0–1.4) 1.2 (1.1–1.4)
Time since first use2 P trend = .08 P trend = .06
1–4 yrs 514 1187 1.1 (0.97–1.3) 1.2 (1.1–1.4)
5–9 yrs 556 1098 1.1 (0.98–1.3) 1.2 (1.0–1.4)
10–14 yrs 294 599 1.0 (0.9–1.2) 0.97 (0.8–1.2)
15+ yrs 128 258 1.1 (0.9–1.4) 0.96 (0.7–1.3)
Time since last use2 P trend = .19 P trend = .51
-1 yr/current use 1381 2908 1.1 (0.99–1.2) 1.2 (1.0–1.3)
1–2 yrs 71 162 0.96 (0.7–1.3) 0.9 (0.6–1.3)
3–4 yrs 31 63 1.0 (0.6–1.6) 1.1 (0.6–1.9)
5+ yrs 9 9 1.7 (0.6–4.3) 2.3 (0.7–7.2)
P trend = .14 P trend = .054
Conditional logistic regression analysis [Odds ratios (OR) and 95% confidence intervals]; adjustment for BMI, family history of breast cancer, 
childbearing history, age at first live birth, duration of breast-feeding, age at menarche, ever OC use, education. Index dates 0.5 = exposure 
information was not considered 0.5 year prior to cancer diagnosis.
1 e-case, e-ctrl = number of observations for exposed case or exposed control respectively.
2 time variables were roundedBMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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were seen comparing the two strata of age and ever use of
OCs, i.e. higher BC risk associated with HRT use in
women with higher age, and for women with no past his-
tory of OC use. In addition, there is evidence that the
effect of HRT on BC risk is more pronounced in women
with lower education level, higher BMI, earlier menarche,
fewer births, but surprisingly also with prevalence of
breast-feeding.
To our surprise, there seemed to be a lower impact of HRT
use on BC risk with increasing duration of past use of OCs,
which needs further attention in future studies. The
adjusted BC risk estimates were according to duration of
OC use: never use [1.38 (1.04–1.84)], up to 2 years OC
use [0.96 (0.39–2.34)], 2–4 years [not sufficient numbers
for conditional analysis], 5–10 years [0.89 (0.32–2.41)],
and for 10 and more years [0.72 (0.50–1.05)].
Cancer risk of different HRT formulations
The aim of the analysis of different HRT formulation
groups was to provide a crude, visual comparison of dif-
ferent groups of different HRT formulation across groups.
The name of each formulation category in table 5 means
that at least the labeled substance/combination was used
sometime in life; all other formulation categories, how-
ever, could also have been used at different points in time.
The categories are therefore not mutually exclusive, except
the three categories of CEE/MPA combination.
The number of exposed cases and controls were very dif-
ferent across the subgroups of ever use of estrogens and
progestins during lifetime. If numbers of exposed cases or
controls were less than 5 (in any cell of the two-by-two
table for risk estimation), the ORs were not calculated
(labeled as n.d. = no data). Moreover, the loss of data dur-
Table 4: Risk of breast cancer in HRT users stratified by established risk markers.
Breast cancer
e-case1 e-ctrl.1 Crude OR (95% CI) Adj. OR (95% CI)
Age at diagnosis
<50 years 99 444 0.96 (0.7–1.2) 0.8 (0.6–1.1)
50+ years 1393 2698 1.1 (0.99–1.2) 1.3 (1.1–1.4)
Education P eff = 0.0 P eff = 0.0
University level 455 1089 1.2 (0.96–1.6) 1.1 (0.7–1.5)
Lower education 1037 2053 1.2 (1.0–1.3) 1.3 (1.1–1.5)
Age at menarche P eff = 0.0 P eff = 0.0
<13 years 764 1600 1.1 (0.9–1.3) 1.1 (0.9–1.3)
13+ years 728 1542 1.1 (0.9–1.3) 1.0 (0.8–1.3)
Child bearing history P eff = 0.0 P eff = 0.0
0–1 child 678 1167 1.1 (0.9–1.3) 1.1 (0.8–1.4)
2+ children 814 1975 1.0 (0.9–1.2) 1.0 (0.9–1.2)
Age at first live birth P eff = 0.0 P eff = 0.0
<= 22 years 593 1255 1.1 (0.9–1.3) 1.2 (0.9–1.5)
>22 years 700 1554 1.2 (0.97–1.4) 1.2 (0.95–1.5)
Breast-feeding P eff = 0.0 P eff = 0.0
never 838 1552 1.1 (0.9–1.2) 1.1 (0.91–1.4)
1 month and more 654 1590 1.1 (0.96–1.4) 1.3 (1.0–1.6)
OC use P eff = 0.0 P eff = 0.0
never 461 695 1.3 (0.99–1.6) 1.4 (1.0–1.8)
ever 1031 2447 1.2 (1.0–1.3) 1.1 (0.9–1.3)
Family history of breast cancer P eff = 0.0 P eff = 0.0
No 1261 2871 1.1 (0.97–1.2) 1.1 (1.0–1.3)
Yes 231 271 5.3 (1.8–15.5) 6.4 (1.7–24.5)
Body mass index P eff = 0.0 P eff = 0.0
<25 617 1546 1.2 (0.99–1.5) 0.99 (0.8–1.3)
25+ 875 1596 1.0 (0.9–1.2) 1.2 (1.0–1.5)
P eff = 0.0 P eff = 0.0
Conditional logistic regression: Odds ratios and 95% confidence intervals. Crude and adjusted for age, BMI, family history of breast cancer, 
childbearing history, age at first live birth, duration of breast-feeding, age at menarche, age at first OC use, education. Analyses for index date 0.5 
year prior to cancer diagnosis.
1 e-case, e-ctrl = number of observations for exposed case or exposed control respectively.
P eff = Significance for effect modificationB
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) Table 5: Risk of breast cancers associated with different categories of HRT formulation or administration.
Ever use Duration of use
1–4 years 5–9 years 10+ years
Formulation categories e-cas/e-ctrl Adj. OR (95% CI) e-cas/e-ctrl Adj. OR (95% CI) e-cas/e-ctrl Adj. OR (95% CI) e-cas/e-ctrl Adj. OR (95% CI)
A. Route of administration
oral 1053/2321 1.1 (0.99 – 1.3) 249/769 0.9 (0.7 – 1.1) 405/750 1.3 (0.7 – 1.1) 295/474 1.5 (1.2 – 1.9)
transdermal 211/650 0.8 (0.6 – 1.1) 60/212 0.7 (0.5 – 1.0) 81/189 1.1 (0.7 – 1.8) 52/161 0.9 (0.5 – 1.4)
other 94/307 0.7 (0.5 – 0.98) 23/98 0.5 (0.3 – 1.1) 24/78 0.6 (0.3 – 1.2) 28/81 0.7 (0.4 – 1.3)
Only – HRTs
Estrogen (exclusive) 368/1168 0.8 (0.7 – 1.0) 82/341 0.7 (0.5 – 0.97) 140/365 0.99 (0.7 – 1.4) 107/311 0.8 (0.5 – 1.1)
Progestagen (exclusive) 108/321 1.0 (0.7 – 1.4) 30/104 0.8 (0.4 – 1.5) 29/74 1.8 (0.9 – 3.7) 35/75 0.96 (0.5 – 1.8)
Combination – HRTs
Sequential formulations 546/1370 0.9 (0.8–1.1) 129/453 0.8 (0.6–1.1) 224/489 1.0 (0.8–1.3) 150/266 1.3 (0.96 – 1.9)
Continuous-combined 484/802 1.5 (1.2–1.8) 103/257 0.96 (0.7 – 1.4) 197/263 1.9 (1.4–2.6) 141/183 1.98 (1.4–2.9)
All E+P 916/1931 1.2 (1.0–1.3) 223/645 0.9 (0.7–1.0) 360/662 1.3 (1.0–1.6) 248/373 1.6 (1.2–2.0)
CEE/MPA combinations
CEE + MPA 87/192 1.1 (0.7–1.7) 26/72 0.8 (0.4–1.6) 37/56 1.3 (0.7–2.7) 14/40 1.1 (0.4–3.1)
CEE or MPA 359/890 0.9 (0.7–1.2) 54/263 0.6 (0.4–0.99) 133/305 0.9 (0.7–1.3) 135/222 1.2 (0.9–1.8)
No CEE, no MPA 806/1723 1.2 (1.0–1.4) 224/611 0.94 (0.8–1.2) 293/517 1.4 (1.1–1.7) 194/306 1.6 (1.2–2.2)
B. Formulation content
Estrogen type
Estriol (E3) 12/40 0.4 (0.1 – 1.5) 1/11 n.d. 1/9 n.d. 6/8 0.4 (0.1 – 2.6)
Estradiol (E2) 889/2015 1.0 (0.9–1.2) 218/694 0.8 (0.7–1.0) 346/622 1.3 (1.1–1.4) 241/417 1.4 (1.1–1.7)
Ethinylestradiol (EE)* 11/41 0.8 (0.3–2.4) 4/15 n.d 4/6 n.d. 3/16 n.d.
Conjugated equine estrogens 
(CEE)
395/934 1.0 (0.8–1.2) 63/273 0.7 (0.5–1.0) 154/321 0.9 (0.7–1.3) 137/243 1.4 (0.98–2.0)
Progestin type
Norethindrone acetate (NETA) 529/1037 1.2 (0.99–1.4) 114/346 0.8 (0.6–1.1) 209/338 1.4 (1.1–1.9) 157/218 1.9 (1.3–2.6)
Norgestrel (NG) 21/67 0.9 (0.4–2.2) 4/13 n.d. 7/28 0.6 (0.1–2.9) 6/19 0.7 (0.1–4.2)
LNG 290/562 1.3 (0.98–1.6) 69/177 1.2 (0.8–1.9) 131/227 1.4 (0.99–2.0) 69/109 1.3 (0.8–2.3)
Medroxyprogesterone acetate 
(MPA)
138/340 0.96 (0.7–1.3) 43/134 0.8 (0.4–1.3) 53/96 1.3 (0.7–2.3) 26/59 0.8 (0.4–1.7)
CMA 33/96 0.8 (0.5–1.5) 13/32 1.1 (0.4–3.1) 3/18 n.d. 12/21 0.7 (0.2–2.0)
CPA 33/116 0.6 (0.4–1.1) 11/54 0.5 (0.2–1.3) 11/22 1.2 (0.4–3.4) 7/18 0.6 (0.1–2.7)
Medrogestone 141/434 0.7 (0.5–1.0) 16/117 0.5 (0.2–0.9) 55/172 0.5 (0.3–0.9) 60/107 1.3 (0.8–2.2)
Dydrogesterone 9/51 0.5 (0.2–1.2) 2/20 n.d. 3/9 n.d. 2/12 n.d.
Progesterone 7/33 1.4 (0.4–4.4) 4/12 n.d. 1/6 n.d. 1/5 n.d.
Dienogest 10/24 0.9 (0.2–3.4) 1/12 n.d. 4/5 n.d. 3/3 n.d.
Tibolone 17/61 0.8 (0.3–2.1) 7/21 1.8 (0.4–8.3) 5/16 0.98 (0.1–7.9) 3/19 n.d.
The categories are not mutually exclusive – (see text). Conditional logistic regression: Odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age and residency. No OR was calculated if the 
frequency of exposed cases or controls was less than 5 women. This applied for use of HRTs containing desogestrel, lynestrenol, hydroxyprogesterone, and raloxifene. Only the index date 0.5 years is 
depicted in this table.
n.d. = no data.
* = in oral contraceptives used as HRTBMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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ing adjustment may leads in some instances also to the
label "n.d.". Table 5 contains only risk estimates (and
95% confidence interval) for index date 0.5 year. In addi-
tion, the table is stratified by duration of use – to the
extent numbers permitted ("rule of 5"- see above).
We distinguished between different routes of administra-
tion (oral, transdermal, and other), between therapy with
exclusive use of estrogens or progestins throughout the
entire lifetime (i.e. no other HRT was ever used), we con-
sidered two different estrogen/progestin combinations
(sequential and continuous-combined), focused on the
use of CEE and MPA specifically, and examined different
estrogens and progestins.
The oral route of administration dominated in the partic-
ipants of our study. HRT use of the oral route showed a
mainly non-significant association with BC risk, which
shows an increasing trend of risk with longer duration of
use, i.e. becoming significant after 10 and more years of
use. Transdermal use, however, did not show an increased
risk of BC as did other forms of administration.
The BC risk associated with different formulation catego-
ries is small, and often not significantly different from
never-use (as referent category = 1.0). Risk estimates for
some formulation categories seem to be lower than unity
(e.g., for estrogen only), others showed slightly, but signif-
icantly increased risk (e.g. continuous combined regi-
mens) – if numbers are taken at face value.
Mono-therapies with estrogens or progestins seem to be
different. Whereas exclusive estrogen use seems not to be
associated with an increased risk of BC (even a non-signif-
icant tendency toward lower risk) than never use and
depict no trend with increasing duration, "progestin-
only" is also not significantly associated with BC risk but
seems to show a trend of increasing risk with increasing
duration of use.
Taken at face value, continuous combined regimens were
associated with higher risk estimates (mostly significant)
than sequential regimens (mainly non-significant). All
E+P formulations together were associated with margin-
ally higher BC risk estimates than estrogen- or progesta-
gen-only formulations.
As far as CEE and MPA are concerned – no noteworthy
increases in risk were evident if used combined or sepa-
rately. Taking risk estimates at face value, there is no dif-
ference in risk when compared to all other formulations
not containing CEE or MPA (confidence intervals largely
overlapping).
Of the progestins, only NETA showed a slightly increased
BC risk estimates. NETA showed – unlike all other pro-
gestins – an apparent upward trend with increasing dura-
tion of use. Small numbers and large confidence intervals
should be considered.
Discussion
Cancer of the breast is the most commonly occurring can-
cer in women, and the third most common cancer overall.
Incidence and mortality for this and other gynecological
cancers are still increasing in many parts of the world,
especially in developed societies.
An expert panel from the American Institute of Cancer
Research published an extensive review on "Food, Nutri-
tion and the Prevention of Cancer", with consideration of
all potential risk factors, beside others, also external use of
hormones [21]. The panel included factors that probably
act early in life, as well as others that might be lifestyle-
related. Factors that increase the risk of breast cancer in
particular include rapid early growth and greater adult
height, but also a diet low in vegetables and fruit, alcohol
consumption, weight gain in adult life, and high body
mass after menopause [21]. The clearest non-dietary risk
factors were those associated with hormonal and repro-
ductive factors, such as nulliparity, late age at first preg-
nancy, late menopause, but also some inherited
abnormalities that find expression e.g. in a positive family
history. The mechanism by which hormonal factors may
affect carcinogenesis at different gynecological sites was
considered as unclear. It was thought that they may possi-
bly play a promotional role [21]. The similarity of risk fac-
tors (including effects of exogenous hormones) across
more or less all non-communicable diseases is striking
and gives rise to speculation about non-specific, non-
causal associations with gynecological tumors [22], for
example.
Analysis of the effect of external hormones on gynecolog-
ical cancer must take into account the lag time of cancer
development. Lag time is likely to be long and may vary
depending on complex unknown causal mechanisms,
and is therefore an issue involving complex, time-depend-
ent risk factors. It is difficult for observational studies to
account sufficiently for time-dependent variables. Age,
time, and duration of use are only indicator variables.
Moreover, observational studies in general are prone to
bias and residual confounding, even if their performance
is "state-of-art". This is a methodological problem in par-
ticular, because observed risk estimates were usually small
(less than or around 2.0 or 0.8 at the other side of the risk
continuum), especially those associated with use of HRT/
hormones. Given the great potential for residual con-
founding and bias, even a statistically significant small
association might be inconclusive, because such associa-BMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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tions could well be situated below reliable resolution lev-
els of the "epidemiological microscope", i.e. it is not
possible to discriminate between causation and bias/con-
founding [22,23].
Since most of the epidemiological studies before 2002
were performed in North America, and therefore prima-
rily analyzed conjugated equine estrogens with or without
MPA, we were interested in results for other HRT formula-
tions more common in Europe; i.e. HRTs containing CEE
were used by only 10% of our control and BC cases. Our
register-based, case-control study showed marginally
increased adjusted BC risk estimates of about 1.2 without
variation with increasing lag time.
A review of the literature shows that an increased risk of
breast cancer is often but not always reported in studies
[12,13]. In a large-scale, pooled breast cancer review by
the Oxford Group [13] containing 51 studies performed
up to 1997, overall risk estimates for breast cancer and
HRT ever-use in the individual studies ranged from 0.6 to
1.4 (often non-significant). In terms of exposure, HRT in
this meta-analysis refers predominantly to conjugated
equine estrogens (unopposed) in relatively high dosages.
The overall summary risk was 1.14, and 1.34 after dura-
tion of at least 5 years. But there was also a group of 10
cohort studies with summary risk of 0.62 compared to
never-use. Some reviews also indicate that the overall risk
of HRT ever-use often shows no association [24,25]. More
recent studies showed BC risk estimates of E+P users up to
about 2fold increase.
Since HRT ever-use is a fairly crude summary indicator of
exposure, it is advisable to look at time-related specifics
such as duration of use and time since first and last expo-
sures. We observed no significant trend toward risk with
increasing duration of HRT use. Short-term use (under 2
years) and use of 8 and more years, however, was associ-
ated with a marginally significant increase in risk (see
Table 3), whereas duration of use between 2 and 7 years
showed no significant relation. Altogether, duration of
use seems no convincing risk factor for BC. This has also
been observed in other studies [26-28]. The possibility
cannot be excluded that short-term risk estimates are
biased, e.g. toward preferential detection of pre-existing
breast cancer in HRT users shortly after the start of treat-
ment, or differential misclassification of HRT exposure
(never-use as opposed to very short duration). Obviously,
the effect of duration of use was not homogeneous across
different HRT formulations, particularly with respect to
progestins.
The lack of a trend for duration of use – in aggregate – in
our study is not congruent with the aggregate findings of
the large-scale meta-analysis by the Oxford Group [13], in
which the pooled risk estimate increased significantly
with increasing duration of use of HRT (largely differing
from the currently used formulations). BC risk estimates
ranged from 1.5 to 2.3 after many years of HRT use in
another review [24], but in one study the risk after 5+
years was 0.9 [29].
Time since first or last use of HRT seems not to play a role
for breast cancer risk in our study; there is no significant
trend with increasing time interval. However, the collabo-
rative re-analysis by the Oxford Group did find such a
trend [13]. It showed a significantly increasing trend of
breast cancer risk with increasing time since first HRT use,
and a decline in risk with increasing recency of use,
although the change in point estimates over time was not
impressive. However, due to the correlation among time
variables, other significant time trends disappeared when
duration and recency of use were taken into account [27].
The risk of BC associated with HRT was fairly consistent
across strata of other established risk factors, i.e. all risk
that we analyzed did show a significant effect modifica-
tion. The differences in BC risk associated with HRT, how-
ever, were small or even not visible despite statistical
significance in some variables such as age at menarche,
child-bearing history, and age at first birth. The clinical
relevance of this effect modification can therefore be ques-
tioned and the role of chance findings in so many sub-
analyses cannot be ignored.
Some risk factors showed substantial effect modification
such as age, education, breast-feeding, and first-degree
family history of BC.
The effect of HRT use seems to be much stronger in
women with a first-degree family history of BC in our
study. Earlier results from the collaborative analysis by the
Oxford Group [13] presented a different conclusion. The
prevalence of first-degree family history is assumed to be
10–15% in BC cases and about 5% in controls [12]; our
study fits into this picture. Internationally, however, the
effects of family history of BC and use of external steroid
hormones show numerous inconsistencies and paradoxes
[12,13,30-33]. Many investigations have found that a pos-
itive family history amplifies the association between hor-
mone use and BC risk, but others have observed no
impact. Family history of BC, however, may not only
reflect shared genes, but also shared environmental/life-
style exposures. It is not trivial to disentangle both effects
– even in family studies. There is definitely not enough
evidence, however, to conclude that family history or
genetic markers are the main causes of BC [12,30]. Thus,
family history of BC and hormone treatment are among
the many established factors and yet unknown agents that
contribute to the risk of developing breast cancer.BMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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HRT effect modification by former OC use seems to be of
particular interest. We found an interesting significant
impact from previous OC use, but there is little material
published internationally on this topic. It seems that no
use of OCs in the past increases the BC risk associated with
HRT use, whereas former OC use showed no increased BC
risk. This needs to be examined and either confirmed or
refuted in further studies.
The association of different HRT formulations with BC
risk suggested interesting results although the numbers
were too small for deriving conclusions – at least for some
of the progestin categories in our study.
We observed that the BC risk estimates were somewhat
higher when HRT was used via the oral route than the
transdermal route and became even significant after 10
years of use – which was not found for transdermal appli-
cation. Another recently published study (E3N-EPIC
cohort) showed also a slightly increasing risk with longer
duration of HRT use via oral route, but not of transdermal
administration [34]. However, the formulations are dif-
ferent in both ways of administration. Therefore it is
important to analyze the BC risk by formulation groups.
Other studies showed differences only when the forma-
tion was considered.
Our study confirmed that no increased BC risk or even
decreased risk was associated with the use of estrogens
alone. This fits in with the results of other studies [26,27],
which have found no significant association or slight
increase of risk [35].
The BC risk for all combined HRT formulations was
slightly higher and increased with longer duration. The
risk was lower for sequential than for continuous-com-
bined formulations. Several recent studies have found
similar results but often with higher risk estimates
[7,24,26,36-38].
The BC risk associated with testosterone-derived pro-
gestins (e.g., NETA, LNG) seems – if taking the risk esti-
mates at face value – to be slightly higher than with
progesterone-derived progestins (e.g., MPA, CMA, CPA,
medrogestone, dydrogesterone) on average but with a
high variation at a low level of relative risk. However, to
postulate a causal difference based on our study would be
highly speculative – considering among others the fragile
dataset of HRT formulation subgroups. It is far from clear,
however, whether the apparently small difference in risk
between progesterone- and testosterone-derived pro-
gestins is clinically meaningful. More general, it is debata-
ble whether the apparent differences in BC risk across
various progestins are real or simply chance findings due
to multiple sub-analyses.
The Million Women Study [4] and the E3N-EPIC cohort
[34] showed for HRT combinations of estrogens with pro-
gesterone- and testosterone-derived progestins increased
BC risk estimates what seems not be supported by the low
risk estimates associated with progesterone-derived pro-
gestins in our study.
In contrast, exclusive use of estrogens during lifetime
seems not to be associated with an increased BC risk.
Also, no evidence was found to confirm our initial
hypothesis that conjugated equine estrogens co-formu-
lated with MPA might be associated with a different risk as
opposed to "natural estrogens" with or without MPA.
More general, there is still uncertainty whether HRT use
can really cause BC cancer induction de novo. A recent
pathobiological review [39] made the convincing point
that the development of cancers from the first malignant
cell to a clinical diagnosis takes many years and therefore
the biological development process is in apparent contra-
diction with results from epidemiological studies showing
increased risk already after 1–6 years. For this and other
reasons discussed, results of epidemiological studies
should be interpreted with great caution.
Limitations and strengths of the study
The cancer-register affiliated case-control study was based
on voluntary participation. There are three main potential
problem areas: self-selection, complex exposure biases,
and recall bias. Although unlikely to differ across HRT for-
mulation type, the self-selection of cases and controls to
participate might be prompted by specific factors that
affect the representativeness for the population. This can-
not be excluded even for cases. Exposed subjects may have
a higher likelihood of being selected into the study. The
direction of this bias is unknown, because women might
be motivated to participate either because they are partic-
ularly health-conscious, or because their health is poor, or
because the used HRT, or for any number of other reasons.
We assume that the results of our study have not substan-
tially affected by self-selection. Moreover women without
tumor may more readily answer "never used HRT" instead
of "short use only" in case they used HRT only a very short
period of time as opposed to tumor cases. This exposure
misclassification would lead to overestimated tumor risk
estimates for short-term use – what we indeed observed in
our study. The effect overlaps with recall bias: Women
with tumors might better recall exposure to HRTs because
they were asked this question frequently in the course of
diagnosis and treatment. Women without tumors might
never have been questioned about their HRT use or may
not even know what it means. This would tend to increase
the tumor risk associated with HRT use. Since the BC riskBMC Women's Health 2006, 6:13 http://www.biomedcentral.com/1472-6874/6/13
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estimates were relatively low, we think that these biases
were not dominant in our study.
Another potential source of bias is diagnostic suspicion
bias. It cannot be assumed that tumor cases are equally
identified (diagnosed) among HRT users and non-users.
For instance, HRT users may be routinely advised by pre-
scribing physicians to participate in screenings (e.g.,
repeated mammographies). Unfortunately, we could not
control for the number of previous mammographies. This
would lead to overestimated risk estimates. In addition,
the possibility cannot be excluded e.g. that the women
and/or their physicians were aware of "warning signs"
(e.g. lumps, suspicious areas in imaging tests) that may
have led to the decision not to use HRT in the year prior
to final BC diagnosis. This exposure indication bias may
have worked differentially, i.e. more often in later con-
firmed cancer cases than in controls. Stratification by
index dates (increasing lag times) would help to identify
the effect of such a bias that was not observed in our study.
In most of our analyses we chose to disregard exposure at
least 6 month prior to diagnosis/interview. Other authors
decided to lag exposure by one year for the same reason-
ing [34].
An important paper was recently published closely related
with this methodological discussion [11]. The WHI study
provided evidence [11] that controlling for the time of ini-
tiating E+P use and confounding, the risk estimates
became more similar between the WHI clinical trial and
the WHI observational study. We used several approaches
to consider time of exposure and confounding in our
study based on lifetime history.
With regard to lifetime history of exposure, we were una-
ble to compare mutually exclusive groups of different
HRT formulations. Even if the hypothesis were acceptable
that substantial differences in BC risk associated with dif-
ferent estrogens, progestins, and combinations would still
be detectable despite dilution by overlapping exposure to
different formulations during the lifetime, we cannot be
certain. There is much room for speculation.
Despite some advantages of our study over many others in
considering time-dependent exposure during the lifetime,
or in introducing different lag times to perform stratified
analyses, we don't know the impact of the above-men-
tioned biases on the observed risk estimates. Our interpre-
tation of the low BC risk estimates in our observational
study and of the high potential for residual confounding
and bias is that we cannot distinguish between causality
and bias/confounding. In other words, the slightly
increased BC risk estimates associated with HRT use might
well be explained by bias and confounding despite all
efforts to account for them. On the other hand, we cannot
exclude a slightly increased risk of breast cancer associated
with use of HRT either. In addition, we also cannot
exclude a slightly higher BC risk for users of continuous-
combined than of sequential formulation although the
differences were small, i.e. possibly too small to be clini-
cally relevant and too much room for bias to be causal.
Conclusion
Taking the results at face value, ever-use of HRT is associ-
ated with a slightly increased risk of breast cancer. No sig-
nificant trend of increasing BC risk with increasing
duration of HRT use was observed in aggregate. There was,
however, some evidence that the risk of BC might increase
with longer use of some HRT formulation groups. Neither
time since first use nor time since last use of HRT showed
any association with BC risk. Many established BC risk
factors significantly modified the effect of HRT on BC risk.
Apparently, BC risk did not vary markedly among differ-
ent HRT formulations (estrogens, progestins). This should
be interpreted with great caution because of mutually not
exclusive HRT user profiles (subgroups) and small num-
bers. However, there might be differences that were not
detectable in our study due to the "limited solution of the
epidemiological microscope".
We do not feel comfortable distinguishing between causal
associations of BC risk and HRT use in our study and the
effects of residual confounding and bias.
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